Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Hock

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Calcified Tissue International|February 1, 1986
Stimulation of undermineralized matrix formation by 1,25 dihydroxyvitamin D3 in long bones of ratsJ M Hock, M Gunness-Hey, J Poser, et al.
Bone|May 10, 2001
Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbitsT Mashiba, D B Burr, C H Turner, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 10, 2000
Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893A F Stewart, R L Cain, D B Burr, et al.
Journal of Cellular Biochemistry|November 5, 1997
Parathyroid hormone (1-34)-mediated interleukin-6 inductionJ E Onyia, T A Libermann, J Bidwell, et al.
Calcified Tissue International|April 1, 1986
Human parathyroid hormone (1-34) and salmon calcitonin do not reverse impaired mineralization produced by high doses of 1,25 dihydroxyvitamin D3M Gunness-Hey, J M Hock, I Gera, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 1999
Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeysR Brommage, C E Hotchkiss, C J Lees, et al.
Journal of Cellular Biochemistry|January 24, 1998
Topoisomerase II expression in osseous tissueH A Feister, D Swartz, P R Odgren, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatmentMasahiko Sato, Y L Ma, J M Hock, et al.
Bone|March 10, 2000
The expression of the nuclear matrix proteins NuMA, topoisomerase II-alpha, and -beta in bone and osseous cell culture: regulation by parathyroid hormoneH A Feister, J E Onyia, R R Miles, et al.
Calcified Tissue International|March 10, 2006
Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormoneX Yu, J Milas, N Watanabe, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Calcified Tissue International|February 1, 1986
Stimulation of undermineralized matrix formation by 1,25 dihydroxyvitamin D3 in long bones of ratsJ M Hock, M Gunness-Hey, J Poser, et al.
Bone|May 10, 2001
Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbitsT Mashiba, D B Burr, C H Turner, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 10, 2000
Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893A F Stewart, R L Cain, D B Burr, et al.
Journal of Cellular Biochemistry|November 5, 1997
Parathyroid hormone (1-34)-mediated interleukin-6 inductionJ E Onyia, T A Libermann, J Bidwell, et al.
Calcified Tissue International|April 1, 1986
Human parathyroid hormone (1-34) and salmon calcitonin do not reverse impaired mineralization produced by high doses of 1,25 dihydroxyvitamin D3M Gunness-Hey, J M Hock, I Gera, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 1999
Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeysR Brommage, C E Hotchkiss, C J Lees, et al.
Journal of Cellular Biochemistry|January 24, 1998
Topoisomerase II expression in osseous tissueH A Feister, D Swartz, P R Odgren, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatmentMasahiko Sato, Y L Ma, J M Hock, et al.
Bone|March 10, 2000
The expression of the nuclear matrix proteins NuMA, topoisomerase II-alpha, and -beta in bone and osseous cell culture: regulation by parathyroid hormoneH A Feister, J E Onyia, R R Miles, et al.
Calcified Tissue International|March 10, 2006
Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormoneX Yu, J Milas, N Watanabe, et al.
Pageof 7